Lexagene Holdings (Lexagene Holdings) EBIT per Share : $-0.06 (TTM As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings EBIT per Share?

Lexagene Holdings's EBIT per Share for the three months ended in Nov. 2022 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2022 was $-0.06.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lexagene Holdings's EBIT per Share or its related term are showing as below:

LXXGQ's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.75
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Lexagene Holdings's EBIT for the three months ended in Nov. 2022 was $-1.66 Mil.

Lexagene Holdings EBIT per Share Historical Data

The historical data trend for Lexagene Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings EBIT per Share Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

EBIT per Share

Get a 7-Day Free Trial

-0.08

-0.13

-0.10

-0.09

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
EBIT per Share	Get a 7-Day Free Trial															-0.02	-0.02	-0.02	-0.02	-0.01

Lexagene Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lexagene Holdings's EBIT per Share for the fiscal year that ended in Feb. 2022 is calculated as

	EBIT per Share		(A: Feb. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.549	/	119.976
=	-0.09

Lexagene Holdings's EBIT per Share for the quarter that ended in Nov. 2022 is calculated as

	EBIT per Share		(Q: Nov. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.66	/	139.009
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06

Lexagene Holdings (OTCPK:LXXGQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Lexagene Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.